ରେମଡେସିଭିର

ରେମଡେସିଭିର
Clinical data
Pronunciation	/rɛmˈdɛsɪvɪər/ REM-DESS-I-veer
Trade names	Veklury
Synonyms	GS-5734
AHFS/Drugs.com	monograph
MedlinePlus	a620033
data	EU EMA: yes; US DailyMed: Remdesivir;
Pregnancy; category	AU: B2 ; ;
Routes of; administration	Intravenous
ATC code	J05AB16 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only) ; CA: ℞-only ; UK: POM (Prescription only) ; US: ℞-only ; EU: Rx-only ;
Identifiers
	IUPAC name (2S)-2-{(2R,3S,4R,5R)-[5-(4-Aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxy-tetrahydro-furan-2-ylmethoxy]phenoxy-(S)-phosphorylamino}propionic acid 2-ethyl-butyl ester;
CAS Number	1809249-37-3 ;
PubChem CID	121304016;
DrugBank	DB14761 ;
ChemSpider	58827832;
UNII	3QKI37EEHE;
KEGG	D11472;
ChEBI	CHEBI:145994;
ChEMBL	CHEMBL4065616;
ECHA InfoCard	100.302.974
Chemical and physical data
Formula	C27H35N6O8P
Molar mass	୬୦୨.୫୮ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC(COC(=O)[C@@H](NP(=O)(Oc1ccccc1)OC[C@H]1O[C@@]([C@@H]([C@@H]1O)O)(C#N)c1ccc2n1ncnc2N)C)CC;
	InChI InChI=1S/C27H35N6O8P/c1-4-18(5-2)13-38-26(36)17(3)32-42(37,41-19-9-7-6-8-10-19)39-14-21-23(34)24(35)27(15-28,40-21)22-12-11-20-25(29)30-16-31-33(20)22/h6-12,16-18,21,23-24,34-35H,4-5,13-14H2,1-3H3,(H,32,37)(H2,29,30,31)/t17-,21+,23+,24+,27-,42-/m0/s1; Key:RWWYLEGWBNMMLJ-YSOARWBDSA-N;

ରେମଡେସିଭିର, ବ୍ରାଣ୍ଡ ନାମ ଭେକ୍ଲୁରି, ଏକ ଭୂତାଣୂରୋଧୀ ଔଷଧ ଯାହା ଅମ୍ଳଜାନ ଚିକିତ୍ସା ଆବଶ୍ୟକ କରୁଥିବା କିମ୍ବା ଅଧିକ ବିପଦ ପୂର୍ଣ୍ଣ କୋଭିଡ-୧୯ ରୋଗ ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୧୧] ^[୧୨] ନଭେମ୍ବର ୨୦୨୦ ମସିହାରେ ବିଶ୍ୱ ସ୍ୱାସ୍ଥ୍ୟ ସଂଗଠନ ଏହି ରୋଗ ଚିକିତ୍ସା ନିମନ୍ତେ ସର୍ତ୍ତମୂଳକ ସୁପାରିଶ କରିଥିଲା | ଏହା ଶିରାଭ୍ୟନ୍ତର ଇଞ୍ଜେକସନ ଆକାରରେ ୩ରୁ ୧୦ ଦିନ ପର୍ଯ୍ୟନ୍ତ ଦିଆଯାଏ ।^[୧୩] ^[୧୪]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଅଧିକ ଯକୃତ ଏଞ୍ଜାଇମ ନିର୍ଗତ ହୁଏ ଏବଂ ଅଇ ଉଠିଥାଏ | ^[୧୩] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଆଲର୍ଜି ହୋଇପାରେ | ^[୧୫] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର ନିରାପଦ କି ନୁହେଁ ତାହା ଅସ୍ପଷ୍ଟ; ଯଦିଓ ସ୍ତନ୍ୟପାନରେ ନିରାପଦ ଅଛି | ^[୧୬] ଶରୀର ଭିତରେ ରେମଡେସିଭିର ରୁପାନ୍ତର ହୋଇ ଜିଏସ-୪୪୧୫୨୪ ଟ୍ରାଇଫସଫେଟରେ ପରିଣତ ହୋଇଥାଏ ଯାହା ଭୂତାଣୁ ଆରଏନଏ ପଲିମରେଜର ଏକ ରାଇବୋନିଉକ୍ଲିଓଟାଇଡ ଅନାଲଗ ଇନହିବିଟର ।^[୧୭]

ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଅକ୍ଟୋବର ୨୦୨୦ ମସିହାରେ ଆମେରିକାରେ ଓ ଜୁଲାଇ ୨୦୨୦ ମସିହାରେ ୟୁରୋପରେ ଅନୁମୋଦିତ ହୋଇଥିଲା ^[୧୨] ^[୧୮] ଏହା ଗିଲିଡ ବିଜ୍ଞାନ କମ୍ପାନୀଦ୍ୱାରା ବିକଶିତ ହୋଇଥିଲା ଯାହା ମୂଳତଃ ହେପାଟାଇଟିସ ସି, ଇବୋଲା ଭୂତାଣୁ ରୋଗ, ଏବଂ ମାରବର୍ଗ ଭୂତାଣୁ ରୋଗ ଚିକିତ୍ସା ନିମନ୍ତେ ଅନୁଶୀଳନ କରାଯାଇଥିଲା ।^[୧୯] ^[୨୦] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୨୧ ମସିହା ସୁଦ୍ଧା ପାଞ୍ଚ ଦିନ ପାଇଁ ଏହାର ମୂଲ୍ୟ ପ୍ରାୟ ୨,୬୦୦ ଡଲାର ଥିଲା | ^[୨୧] ବ୍ରିଟେନରେ ଏହି ରାଶି ପ୍ରାୟ ୨,୦୪୦ ପାଉଣ୍ଡ ଅଟେ | ^[୨୨]

ଆଧାର

↑ ^୧.୦ ^୧.୧ "Veklury Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 13 July 2020. Archived from the original on 13 August 2020. Retrieved 16 August 2020.
↑ "Veklury Powder for Injection Product Information". Therapeutic Goods Administration (TGA). 9 June 2021. Retrieved 16 August 2020.
↑ "Veklury remdesivir 100 mg powder for injection vial". Therapeutic Goods Administration (TGA). Archived from the original on 23 October 2021. Retrieved 22 October 2021.
↑ "COVID-19 treatment: Gilead Sciences Pty Ltd, remdesivir (Veklury)". Therapeutic Goods Administration (TGA). 10 July 2020. Archived from the original on 21 October 2021. Retrieved 22 October 2021.
↑ "Veklury Product information". Health Canada. 25 April 2012. Archived from the original on 26 October 2020. Retrieved 22 October 2020.
↑ ଆଧାର ଭୁଲ: ଅଚଳ <ref> ଚିହ୍ନ; Veklury EPAR ନାମରେ ଥିବା ଆଧାର ଭିତରେ କିଛି ଲେଖା ନାହିଁ ।
↑ "Veklury 100 mg concentrate for solution for infusion – Summary of Product Characteristics (SmPC)". (emc). 6 July 2020. Archived from the original on 24 November 2020. Retrieved 4 October 2020.
↑ "Veklury 100 mg powder for concentrate for solution for infusion – Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 8 October 2020. Retrieved 4 October 2020.
↑ "Remdesivir injection Remdesivir injection, powder, lyophilized, for solution". DailyMed. 1 September 2020. Archived from the original on 26 September 2020. Retrieved 25 September 2020.
↑ ଆଧାର ଭୁଲ: ଅଚଳ <ref> ଚିହ୍ନ; FDA PR 20201022 ନାମରେ ଥିବା ଆଧାର ଭିତରେ କିଛି ଲେଖା ନାହିଁ ।
↑ "Remdesivir Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 13 July 2021.
↑ ^୧୨.୦ ^୧୨.୧ "Veklury EPAR". European Medicines Agency (EMA). 23 June 2020. Retrieved 6 July 2020.
↑ ^୧୩.୦ ^୧୩.୧ "Remdesivir Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 13 July 2021.
↑ "Statement on Therapies for High-Risk, Nonhospitalized Patients". COVID-19 Treatment Guidelines (in ଇଂରାଜୀ). Archived from the original on 7 January 2022. Retrieved 7 January 2022.
↑ "Fact Sheet for Patients And Parent/Caregivers Emergency Use Authorization (EUA) Of Remdesivir For Coronavirus Disease 2019 (COVID-19)" (PDF). U.S. Food and Drug Administration (FDA). Retrieved 8 May 2020.
↑ "Remdesivir (Veklury) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Retrieved 13 July 2021.
↑ Yan, Victoria C.; Muller, Florian L. (14 May 2020). "Gilead should ditch remdesivir and focus on its simpler and safer ancestor". Stat. Boston Globe Media Partners.
↑ "New Drug Therapy Approvals 2020". U.S. Food and Drug Administration (FDA). 31 December 2020. Retrieved 17 January 2021.
↑ Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, Berrino L, Racagni G, Rossi F, Capuano A (April 2020). "Current pharmacological treatments for COVID-19: What's next?". British Journal of Pharmacology. 177 (21): 4813–4824. doi:10.1111/bph.15072. eISSN 1476-5381. PMC 7264618. PMID 32329520. {{cite journal}}: Unknown parameter |displayauthors= ignored (|display-authors= suggested) (help)
↑ Stephens, Bret (18 April 2020). "The Story of Remdesivir". The New York Times. p. A23. Retrieved 11 May 2020.
↑ Chamary, J. V. "The Strange Story Of Remdesivir, A Covid Drug That Doesn't Work". Forbes (in ଇଂରାଜୀ). Retrieved 13 July 2021.
↑ "6.1. Coronavirus". British National Formulary (BNF) (82 ed.). BMJ Group and the Pharmaceutical Press. September 2021 – March 2022. pp. 665–667. ISBN 978-0-85711-413-6.{{cite book}}: CS1 maint: date format (link)

[Veklury_APM_summary-1] ୧.୦ ^୧.୧ "Veklury Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 13 July 2020. Archived from the original on 13 August 2020. Retrieved 16 August 2020.

[2] "Veklury Powder for Injection Product Information". Therapeutic Goods Administration (TGA). 9 June 2021. Retrieved 16 August 2020.

[3] "Veklury remdesivir 100 mg powder for injection vial". Therapeutic Goods Administration (TGA). Archived from the original on 23 October 2021. Retrieved 22 October 2021.

[4] "COVID-19 treatment: Gilead Sciences Pty Ltd, remdesivir (Veklury)". Therapeutic Goods Administration (TGA). 10 July 2020. Archived from the original on 21 October 2021. Retrieved 22 October 2021.

[CA_Veklury_Product_information-5] "Veklury Product information". Health Canada. 25 April 2012. Archived from the original on 26 October 2020. Retrieved 22 October 2020.

[Veklury_EPAR-6] ଆଧାର ଭୁଲ: ଅଚଳ <ref> ଚିହ୍ନ; Veklury EPAR ନାମରେ ଥିବା ଆଧାର ଭିତରେ କିଛି ଲେଖା ନାହିଁ ।

[Veklury_SmPC-7] "Veklury 100 mg concentrate for solution for infusion – Summary of Product Characteristics (SmPC)". (emc). 6 July 2020. Archived from the original on 24 November 2020. Retrieved 4 October 2020.

[8] "Veklury 100 mg powder for concentrate for solution for infusion – Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 8 October 2020. Retrieved 4 October 2020.

[Remdesivir_FDA_label-9] "Remdesivir injection Remdesivir injection, powder, lyophilized, for solution". DailyMed. 1 September 2020. Archived from the original on 26 September 2020. Retrieved 25 September 2020.

[FDA_PR_20201022-10] ଆଧାର ଭୁଲ: ଅଚଳ <ref> ଚିହ୍ନ; FDA PR 20201022 ନାମରେ ଥିବା ଆଧାର ଭିତରେ କିଛି ଲେଖା ନାହିଁ ।

[AHFS2021-11] "Remdesivir Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 13 July 2021.

[EU2021-12] ୧୨.୦ ^୧୨.୧ "Veklury EPAR". European Medicines Agency (EMA). 23 June 2020. Retrieved 6 July 2020.

[autogen1-13] ୧୩.୦ ^୧୩.୧ "Remdesivir Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 13 July 2021.

[NIH2021Dec-14] "Statement on Therapies for High-Risk, Nonhospitalized Patients". COVID-19 Treatment Guidelines (in ଇଂରାଜୀ). Archived from the original on 7 January 2022. Retrieved 7 January 2022.

[Fact2022-15] "Fact Sheet for Patients And Parent/Caregivers Emergency Use Authorization (EUA) Of Remdesivir For Coronavirus Disease 2019 (COVID-19)" (PDF). U.S. Food and Drug Administration (FDA). Retrieved 8 May 2020.

[Preg2021-16] "Remdesivir (Veklury) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Retrieved 13 July 2021.

[Yan_2020-17] Yan, Victoria C.; Muller, Florian L. (14 May 2020). "Gilead should ditch remdesivir and focus on its simpler and safer ancestor". Stat. Boston Globe Media Partners.

[FDA2020Aprov-18] "New Drug Therapy Approvals 2020". U.S. Food and Drug Administration (FDA). 31 December 2020. Retrieved 17 January 2021.

[Scavone_2020-19] Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, Berrino L, Racagni G, Rossi F, Capuano A (April 2020). "Current pharmacological treatments for COVID-19: What's next?". British Journal of Pharmacology. 177 (21): 4813–4824. doi:10.1111/bph.15072. eISSN 1476-5381. PMC 7264618. PMID 32329520. {{cite journal}}: Unknown parameter |displayauthors= ignored (|display-authors= suggested) (help)

[Stephens2-20] Stephens, Bret (18 April 2020). "The Story of Remdesivir". The New York Times. p. A23. Retrieved 11 May 2020.

[21] Chamary, J. V. "The Strange Story Of Remdesivir, A Covid Drug That Doesn't Work". Forbes (in ଇଂରାଜୀ). Retrieved 13 July 2021.

[BNF82-22] "6.1. Coronavirus". British National Formulary (BNF) (82 ed.). BMJ Group and the Pharmaceutical Press. September 2021 – March 2022. pp. 665–667. ISBN 978-0-85711-413-6.{{cite book}}: CS1 maint: date format (link)

[୧]

[୨]

[୩]

[୪]

[୫]

[୭]

[୮]

[୯]

[୧୦]

[୬]

[୧୧]

[୧୨]

[୧୩]

[୧୪]

[୧୫]

[୧୬]

[୧୭]

[୧୮]

[୧୯]

[୨୦]

[୨୧]

[୨୨]